Semaglutide and cancer: A systematic review and meta-analysis.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Semaglutide and cancer: A systematic review and meta-analysis.
- Published In:
- Diabetes & metabolic syndrome, 17(9), 102834 (2023)
- Authors:
- Nagendra, Lakshmi(7), Bg, Harish, Sharma, Meha(5), Dutta, Deep
- Database ID:
- RPEP-07213
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07213APA
Nagendra, Lakshmi; Bg, Harish; Sharma, Meha; Dutta, Deep. (2023). Semaglutide and cancer: A systematic review and meta-analysis.. Diabetes & metabolic syndrome, 17(9), 102834. https://doi.org/10.1016/j.dsx.2023.102834
MLA
Nagendra, Lakshmi, et al. "Semaglutide and cancer: A systematic review and meta-analysis.." Diabetes & metabolic syndrome, 2023. https://doi.org/10.1016/j.dsx.2023.102834
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide and cancer: A systematic review and meta-analysi..." RPEP-07213. Retrieved from https://rethinkpeptides.com/research/nagendra-2023-semaglutide-and-cancer-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.